<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04042558</url>
  </required_header>
  <id_info>
    <org_study_id>GFPC 06-2018</org_study_id>
    <nct_id>NCT04042558</nct_id>
  </id_info>
  <brief_title>A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies</brief_title>
  <acronym>GFPC 06-2018</acronym>
  <official_title>A Multicentre Phase II, Open-label, Non-randomized Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/- Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GFPC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the efficacy of the combination of Platinum&#xD;
      (carboplatin or cisplatin), Pemetrexed, Atezolizumab+/- Bevacizumab if eligible, in stage&#xD;
      IIIB/IV non-squamous non-small cell lung cancer patients with progression-enhancing mutations&#xD;
      following targeted therapies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with an EGFR mutation, several phase III studies comparing EGFR tyrosine kinase&#xD;
      inhibitors (TKIs) with chemotherapy have shown a benefit of TKI over chemotherapy, with no&#xD;
      demonstrated benefit on overall survival. After a first line of treatment with a TKI, most&#xD;
      patients progress and are eligible according to the mechanism of progression to a TKI of 3rd&#xD;
      generation in case of T790M resistance or chemotherapy. In patients with ALK translocation,&#xD;
      crizotinib has been shown to be beneficial in first line compared to a platinum&#xD;
      doublet.Despite these major advances, most patients are progressing after targeted treatments&#xD;
      and chemotherapy and are facing the problem of anti-PD1 / PDL1 treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 26, 2019</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open-label, multicentre, non-randomized two parallel cohorts phase II study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) according to RECIST 1.1</measure>
    <time_frame>After the end of 4 cycles (15 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The progression-free survival (PFS)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The duration of response</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">149</enrollment>
  <condition>NSCLC Stage IIIB</condition>
  <condition>NSCLC Stage IV</condition>
  <condition>EGFR Gene Mutation</condition>
  <condition>ALK Gene Rearrangement Positive</condition>
  <condition>ROS1 Gene Mutation</condition>
  <arm_group>
    <arm_group_label>Cohort with Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 cycles of induction every 3 weeks with :&#xD;
Carboplatin area under curve 6 mg/mL per minute per IV route or Cisplatin 75 mg/m² per IV route&#xD;
Pemetrexed 500 mg/m² per IV route&#xD;
Atezolizumab 1200 mg per IV route&#xD;
Bevacizumab 15 mg/kg per IV route For patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed and Bevacizumab administered at the same dosage on 3-week cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort without Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 cycles of induction every 3 weeks with :&#xD;
Carboplatin area under curve 6 mg/mL per minute per IV route or Cisplatin 75 mg/m² per IV route&#xD;
Pemetrexed 500 mg/m² per IV route&#xD;
Atezolizumab 1200 mg per IV route For patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed administered at the same dosage on 3-week cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab</intervention_name>
    <description>4 cycles of induction every 3 weeks of cisplatine,pemetrexed, atezolizumab + bevacizumab and patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed +/- Bevacizumab administered at the same dosage on 3-week cycles</description>
    <arm_group_label>Cohort with Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin + Pemetrexed + Atezolizumab</intervention_name>
    <description>Carboplatin + Pemetrexed + Atezolizumab</description>
    <arm_group_label>Cohort without Bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient older than 18 years&#xD;
&#xD;
          -  Subject affiliated to an appropriate social security system&#xD;
&#xD;
          -  Signed informed consent before any trial related activities and according to local&#xD;
             guidelines&#xD;
&#xD;
          -  ECOG performance status of 0 or 1&#xD;
&#xD;
          -  Histologically or cytologically confirmed, stage IIIB/IV non-squamous NSCLC (per the&#xD;
             Union Internationale contre le Cancer/American Joint Committee on Cancer staging&#xD;
             system, 7th edition).&#xD;
&#xD;
          -  Patient with a sensitizing mutation in the EGFR gene must have experienced disease&#xD;
             progression (during or after treatment) or intolerance to treatment with one or more&#xD;
             EGFR TKIs, such as erlotinib, gefitinib, osimertinib or another EGFR TKI appropriate&#xD;
             for the treatment of EGFR-mutant NSCLC. Patients with stage IIIB had to be not&#xD;
             operable (that means not eligible for radiochemotherapy followed by a maintenance&#xD;
             treatment by Durvalumab)&#xD;
&#xD;
          -  Patient with an ALK fusion oncogene (confirmed in local laboratory) must have&#xD;
             experienced disease progression (during or after treatment) or intolerance to&#xD;
             treatment with one or more ALK inhibitors (i.e., crizotinib, alectinib, ceritinib)&#xD;
             appropriate for the treatment of NSCLC in patients having an ALK fusion oncogene&#xD;
&#xD;
          -  Patient with a ROS1 fusion oncogene (confirmed in local laboratory) must have&#xD;
             experienced disease progression (during or after treatment) or intolerance to&#xD;
             treatment with one or more ROS inhibitors (i.e., crizotinib,) appropriate for the&#xD;
             treatment of NSCLC in patients having an ROS1 fusion oncogene&#xD;
&#xD;
          -  No prior chemotherapy treatment for Stage IV non-squamous NSCLC except if less than 3&#xD;
             cycles, with treatment free-interval of at least 1 year from C1 since last&#xD;
             chemotherapy&#xD;
&#xD;
          -  Patient who has received prior neo-adjuvant, adjuvant chemotherapy, radiotherapy, or&#xD;
             chemoradiotherapy with curative intent for non-metastatic disease must have&#xD;
             experienced a treatment-free interval of at least 6 months from C1since the last&#xD;
             chemotherapy, radiotherapy, or chemoradiotherapy&#xD;
&#xD;
          -  Patient with an history of asymptomatic CNS metastases is eligible, provided he meets&#xD;
             all of the following criteria:&#xD;
&#xD;
               -  Only supratentorial and cerebellar metastases allowed (i.e., no metastases to&#xD;
                  midbrain, pons, medulla, or spinal cord)&#xD;
&#xD;
               -  No ongoing requirement for corticosteroids as therapy for CNS disease&#xD;
&#xD;
               -  No stereotactic radiation within 7 days or whole-brain radiation within 14 days&#xD;
                  prior to inclusion&#xD;
&#xD;
          -  Measurable disease, as defined by RECIST v1.1&#xD;
&#xD;
          -  Adequate hematologic and end-organ function, defined by the following laboratory&#xD;
&#xD;
          -  Adequate method of contraception during the treatment period and at least 5 months&#xD;
             after the last dose of atezolizumab or 6 months after the last dose of chemotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Cancer-specific exclusions&#xD;
&#xD;
          -  Active CNS metastases as determined by CT or magnetic resonance imaging (MRI)&#xD;
             evaluation during screening and prior radiographic assessments&#xD;
&#xD;
          -  Spinal cord compression not definitively treated with surgery and/or radiation or&#xD;
             previously diagnosed and treated spinal cord compression without evidence that disease&#xD;
             has been clinically stable for &gt; or = 2 weeks prior to C1&#xD;
&#xD;
          -  Leptomeningeal disease (Presence of cancer cells in cerebral CSF or MRI with&#xD;
             leptomeningeal lesion strongly suspected of leptomeningeal disease )&#xD;
&#xD;
          -  Uncontrolled tumour-related pain&#xD;
&#xD;
          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent&#xD;
             drainage procedures (once monthly or more frequently); Patients with indwelling&#xD;
             catheters (e.g., PleurX) are allowed.&#xD;
&#xD;
          -  Uncontrolled or symptomatic hypercalcemia (&gt;1.5 mmol/L ionized calcium or calcium &gt;12&#xD;
             mg/dL or corrected serum calcium &gt; ULN)&#xD;
&#xD;
          -  Malignancies other than NSCLC within 5 years prior to C1, with the exception of those&#xD;
             with a negligible risk of metastasis or death treated with expected curative outcome&#xD;
             (such as adequately treated carcinoma in situ of the cervix, basal or squamous-cell&#xD;
             skin cancer, localized prostate cancer treated surgically with curative intent, ductal&#xD;
             carcinoma in situ treated surgically with curative intent)&#xD;
&#xD;
        General medical exclusions&#xD;
&#xD;
          -  Women who are pregnant, lactating, or intending to become pregnant during the study&#xD;
&#xD;
          -  History of severe allergic, anaphylactic, or other hypersensitivity reactions to&#xD;
             chimeric or humanized antibodies or fusion proteins&#xD;
&#xD;
          -  Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster&#xD;
             ovary cells or any component of the atezolizumab formulation&#xD;
&#xD;
          -  History of autoimmune disease, including but not limited to myasthenia gravis,&#xD;
             myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis,&#xD;
             inflammatory bowel disease, vascular thrombosis associated with antiphospholipid&#xD;
             syndrome, Wegener's granulomatosis, Sjogren's syndrome, Guillain-Barré syndrome,&#xD;
             multiple sclerosis, vasculitis, or glomerulonephritis&#xD;
&#xD;
               -  Patients with a history of autoimmune-related hypothyroidism on a stable dose of&#xD;
                  thyroid replacement hormone are eligible for this study.&#xD;
&#xD;
               -  Patients with controlled Type 1 diabetes mellitus on a stable dose of insulin&#xD;
                  regimen are eligible for this study&#xD;
&#xD;
               -  Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with&#xD;
                  dermatologic manifestations only are permitted provided that they meet the&#xD;
                  following conditions:&#xD;
&#xD;
               -  Rash must cover less than 10 percent of body surface area (BSA).&#xD;
&#xD;
               -  No acute exacerbations of underlying condition within the previous 12 months (not&#xD;
                  requiring PUVA [psoralen plus ultraviolet A radiation], methotrexate, retinoids,&#xD;
                  biologic agents, oral calcineurin inhibitors, high-potency or oral steroids)&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis&#xD;
             obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active&#xD;
             pneumonitis on screening chest CT scan; History of radiation pneumonitis in the&#xD;
             radiation field (fibrosis) is permitted.&#xD;
&#xD;
          -  Positive test for HIV. All patients will be tested for HIV prior to C1 into the study;&#xD;
             patients who test positive for HIV will be excluded from the study.&#xD;
&#xD;
          -  Patients with active hepatitis B (chronic or acute; defined as having a positive&#xD;
             hepatitis B surface antigen [HBsAg] test at screening) or hepatitis C. Patients with&#xD;
             past hepatitis B virus (HBV) infection or resolved HBV infection (defined as the&#xD;
             presence of hepatitis B core antibody [HBcAb] and absence of HBsAg) are eligible only&#xD;
             if they are negative for HBV DNA. Patients positive for hepatitis C virus (HCV)&#xD;
             antibody are eligible only if PCR is negative for HCV RNA.&#xD;
&#xD;
          -  Active tuberculosis&#xD;
&#xD;
          -  Severe infections within 4 weeks prior to C1, including, but not limited to,&#xD;
             hospitalization for complications of infection, bacteremia, or severe pneumonia&#xD;
&#xD;
          -  Received therapeutic oral or IV antibiotics within 1 week prior to C1; Patients&#xD;
             receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection&#xD;
             or to prevent chronic obstructive pulmonary disease exacerbation) are eligible.&#xD;
&#xD;
          -  Significant cardiovascular disease, such as New York Heart Association cardiac disease&#xD;
             (Class II or greater), myocardial infarction, or cerebrovascular accident within 3&#xD;
             months prior to inclusion, unstable arrhythmias, or unstable angina&#xD;
&#xD;
          -  Major surgical procedure other than for diagnosis within 28 days prior to C1 or&#xD;
             anticipation of need for a major surgical procedure during the course of the study&#xD;
&#xD;
          -  Any other diseases, metabolic dysfunction, physical examination finding, or clinical&#xD;
             laboratory finding giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates the use of an investigational drug or that may affect the&#xD;
             interpretation of the results or renders the patient at high risk from treatment&#xD;
             complications&#xD;
&#xD;
          -  Symptomatic brain metastases;&#xD;
&#xD;
          -  Patients with illnesses or conditions that interfere with their capacity to&#xD;
             understand, follow and/or comply with study procedures&#xD;
&#xD;
          -  Concurrent participation in any therapeutic clinical trial&#xD;
&#xD;
          -  Patient deprived of liberty or placed under the authority of a tutor&#xD;
&#xD;
          -  Assessed by the investigator to be unable or unwilling to comply with the requirements&#xD;
             of the protocol&#xD;
&#xD;
        Exclusion criteria related to medications&#xD;
&#xD;
          -  Any approved anti-cancer therapy, including hormonal therapy within 7 days prior to C1&#xD;
             of study treatment.&#xD;
&#xD;
          -  Treatment with any other investigational agent with therapeutic intent within 28 days&#xD;
             prior to C1&#xD;
&#xD;
          -  Prior treatment with CD137 agonists or immune checkpoint blockade therapies,&#xD;
             anti-PD-1, and anti-PD-L1 therapeutic antibodies&#xD;
&#xD;
               -  Patients who have had prior anti-cytotoxic T-lymphocyte associated antigen 4&#xD;
                  (CTLA-4) treatment may be enrolled, provided the following requirements are met:&#xD;
&#xD;
               -  Last dose of anti-CTLA-4 at least 6 weeks prior to C1&#xD;
&#xD;
               -  No history of severe immune-related adverse effects from anti-CTLA-4 (NCI CTCAE&#xD;
                  Grade 3/4)&#xD;
&#xD;
          -  Treatment with systemic immunostimulatory agents (including, but not limited to,&#xD;
             interferons, interleukin 2) within 4 weeks or 5 half-lives of the drug, whichever is&#xD;
             longer, prior to C1 ; Prior treatment with cancer vaccines is allowed.&#xD;
&#xD;
          -  Treatment with systemic immunosuppressive medications (including, but not limited to,&#xD;
             corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and&#xD;
             anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to C1&#xD;
&#xD;
        Exclusion criteria related to chemotherapy&#xD;
&#xD;
          -  History of allergic reactions to cisplatin, carboplatin, or other platinum-containing&#xD;
             compounds&#xD;
&#xD;
          -  Patients with hearing impairment (cisplatin)&#xD;
&#xD;
          -  Grade &gt; or = 2 peripheral neuropathy as defined by NCI CTCAE v5.0 (cisplatin)&#xD;
&#xD;
          -  CRCL &lt; 60 mL/min for cisplatin or &lt; 45 mL/min for carboplatin using the&#xD;
             Cockcroft-Gault Method&#xD;
&#xD;
        Exclusion criteria related to Bevacizumab&#xD;
&#xD;
          -  Medically uncontrolled hypertension (defined as PAS&gt;150 and/or PAD &gt;100 mmHg)&#xD;
&#xD;
          -  Prior history of hypertensive crisis or hypertensive encephalopathy&#xD;
&#xD;
          -  Clinically significant cardiovascular disease (within 6 months prior to C1) that is&#xD;
             uncontrolled by medication or may interfere with administration of trial treatment:&#xD;
&#xD;
               -  Aortic aneurysm requiring surgical repair&#xD;
&#xD;
               -  Recent arterial thrombosis&#xD;
&#xD;
               -  Haemoptysis (&gt;one-half teaspoon of bright red blood per episode (within one&#xD;
                  months prior to C1) (grade 2 haemoptysis)&#xD;
&#xD;
          -  History of documented haemorrhagic diathesis or coagulopathy&#xD;
&#xD;
          -  History of abdominal or tracheosphageal fistula or perforation within 6 months prior&#xD;
             to C1&#xD;
&#xD;
          -  Core biopsy or other minor surgical procedure within 7 days before bevacizumab&#xD;
&#xD;
          -  Clinical signs or gastrointestinal obstruction or requirement for routine parenteral&#xD;
             hydration, nutrition or tube feeding&#xD;
&#xD;
          -  Evidence of abdominal free air not explained by paracentesis or recent surgical&#xD;
             procedure&#xD;
&#xD;
          -  Major surgery within 28 days before C1&#xD;
&#xD;
          -  Serious, non-healing wound, active ulcer or untreated bone fracture&#xD;
&#xD;
          -  Proteinuria &gt;1g/24h urine collection&#xD;
&#xD;
          -  All patient with &gt;2+ protein on dipstick urinalysis at baseline must undergo a 24-hour&#xD;
             urine collection and must demonstrate &lt; or = 1g of protein in 24 hours.&#xD;
&#xD;
          -  Known sensitivity to any component of bevacizumab&#xD;
&#xD;
          -  Radiation therapy within 21 days before C1 (except Symptomatic lesions amenable to&#xD;
             palliative radiotherapy)&#xD;
&#xD;
          -  Adequate hematologic, liver, and renal function required (including creatinine&#xD;
             clearance 45 mL/min at baseline and 45 mL/min before the start of any subsequent cycle&#xD;
             using the Cockcroft-Gault Method.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>BYLICKI Olivier, MD</last_name>
    <phone>+33 (0) 1 41 46 62 67</phone>
    <email>bylicki.olivier@yahoo.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>GRELLARD Jean-Michel, Project manager</last_name>
    <phone>+33 (0)2 31 45 50 02</phone>
    <email>jm.grellard@baclesse.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JUSTEAU Gregoire, MD</last_name>
    </contact>
    <investigator>
      <last_name>JUSTEAU Gregoire, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HOMINAL Stéphane, MD</last_name>
    </contact>
    <investigator>
      <last_name>HOMINAL Stéphane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU-Hôpital MORVAN</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DESCOURT Renaud, MD</last_name>
    </contact>
    <investigator>
      <last_name>DESCOURT Renaud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Louis Pradel</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sebastien COURAUD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Sebastien COURAUD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GERVAIS Radj, MD</last_name>
      <phone>+33 (0)2 31 45 51 60</phone>
      <email>r.gervais@baclesse.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>GRELLARD Jean-Michel</last_name>
      <phone>+33 (0)2 31 45 50 02</phone>
      <email>jm.grellard@baclesse.unicancer.fr</email>
    </contact_backup>
    <investigator>
      <last_name>GERVAIS Radj, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Gabriel MONTPIED</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>JANICOT Henri, MD</last_name>
    </contact>
    <investigator>
      <last_name>JANICOT Henri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHIC</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MONNET Isabelle, MD</last_name>
    </contact>
    <investigator>
      <last_name>MONNET Isabelle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MORO-SIBILOT Denis, PhD</last_name>
    </contact>
    <investigator>
      <last_name>MORO-SIBILOT Denis, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHD Vendée La Roche sur Yon</name>
      <address>
        <city>La Roche sur Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Acya BIZIEUX, MD</last_name>
    </contact>
    <investigator>
      <last_name>Acya BIZIEUX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Réunion St Denis</name>
      <address>
        <city>La Réunion</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane MOREAU, MD</last_name>
    </contact>
    <investigator>
      <last_name>Diane MOREAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Réunion St Pierre</name>
      <address>
        <city>La Réunion</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric HUCHOT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eric HUCHOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexis CORTOT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alexis CORTOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VERGNENEGRE Alain, PhD</last_name>
    </contact>
    <investigator>
      <last_name>VERGNENEGRE Alain, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PEROL Maurice, MD</last_name>
    </contact>
    <investigator>
      <last_name>PEROL Maurice, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lyon, Croix-Rousse,</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sebastien COURAUD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Sebastien COURAUD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GREILLER Laurent, PhD</last_name>
    </contact>
    <investigator>
      <last_name>GREILLER Laurent, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR Orléans</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hugues MOREL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hugues MOREL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DOUBRE Helene, MD</last_name>
    </contact>
    <investigator>
      <last_name>DOUBRE Helene, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DANIEL Catherine, MD</last_name>
    </contact>
    <investigator>
      <last_name>DANIEL Catherine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HIA Percy</name>
      <address>
        <city>Percy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BYLICKI Olivier, MD</last_name>
    </contact>
    <investigator>
      <last_name>BYLICKI Olivier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut Lévêque,Centre François Magendie</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VEILLON Rémi, MD</last_name>
    </contact>
    <investigator>
      <last_name>VEILLON Rémi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>COURAUD Sébastien, MD</last_name>
    </contact>
    <investigator>
      <last_name>COURAUD Sébastien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LENA Hervé, MD</last_name>
    </contact>
    <investigator>
      <last_name>LENA Hervé, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BOTA Suzanna, MD</last_name>
    </contact>
    <investigator>
      <last_name>BOTA Suzanna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICLN, St Priez en Jarez</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>FOURNEL Pierre, PhD</last_name>
    </contact>
    <investigator>
      <last_name>FOURNEL Pierre, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SCHOTT Roland, MD</last_name>
    </contact>
    <investigator>
      <last_name>SCHOTT Roland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HIA St Anne</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PALEIRON Nicolas, MD</last_name>
    </contact>
    <investigator>
      <last_name>PALEIRON Nicolas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BIGAY GAME Laurence, MD</last_name>
    </contact>
    <investigator>
      <last_name>BIGAY GAME Laurence, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Bretagne Atlantique</name>
      <address>
        <city>Vannes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gonzague DE CHABOT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gonzague DE CHABOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Villefranche</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ARPIN Dominique, MD</last_name>
    </contact>
    <investigator>
      <last_name>ARPIN Dominique, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HIA R.Picqué</name>
      <address>
        <city>Villenave-d'Ornon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PELONI Jean-Michel, MD</last_name>
    </contact>
    <investigator>
      <last_name>PELONI Jean-Michel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 29, 2019</study_first_submitted>
  <study_first_submitted_qc>August 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2019</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

